Novel SSP-1 compositions and therapeutic and diagnostic uses therefor
AssigneeMillennium BioTherapeutics, Inc.
InventorSean Anthony McCarthy
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery of novel genes encoding Small Secreted Protein-1 (SSP-1) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
Claims61
An isolated nucleic acid comprising a nucleotide sequence encoding an SSP-1 polypeptide.
An isolated nucleic acid comprising a nucleotide sequence which is at least about 80% identical to at least about 50 consecutive nucleotides SEQ ID NO:
- 1 or complement thereof.
An isolated nucleic acid comprising a nucleotide sequence of at least about 20 consecutive nucleotides of SEQ ID NO:
- 1 or 3 or complement thereof.
An isolated SSP-1 polypeptide.
A method for modulating an SSP-1 activity, comprising contacting an SSP-1 polypeptide with a compound which is capable of modulating a SSP-1 activity, such that the SSP-1 activity is modulated.
A method for modulating growth, differentiation, or survival of a cell, comprising contacting the cell with an SSP-1 compound which is capable of modulating cell growth, differentiation, or survival.
A method for treating or preventing a disease caused by or contributed to by an aberrant SSP-1 activity in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound which is capable of modulating a SSP-1 activity, such that the disease is treated or prevented in the subject.
The method of claim 52, wherein the compound is an SSP-1 polypeptide.
A method for treating or preventing a disease associated with an abnormal cell proliferation, differentiation or survival in a subject, comprising administering to the subject a pharmaceutically effective amount of an SSP-1 therapeutic.
A method for identifying a SSP-1 therapeutic, comprising
- (i) combining a SSP-1 protein, a SSP-1 binding partner, and a test compound under conditions wherein, but for the test compound, the SSP-1 protein and SSP-1 binding partner are able to interact;
- and
- (ii) detecting the formation of a SSP-1 protein/SSP-1 binding partner complex, such that a difference in the formation of a SSP-1 protein/SSP-1 binding partner complex in the presence of a test compound relative to the absence of the test compound is indicative that the test compound is a SSP-1 therapeutic.
A method for determining whether a subject is at risk of developing a disease or condition which is caused or contributed to by an aberrant SSP-1 activity, comprising measuring in the subject or in a sample obtained from the subject at least one SSP-1 activity, wherein a difference in the SSP-1 activity relative to the SSP-1 activity in a normal subject indicates that the subject is at risk of developing a disease caused by or contributed to by an aberrant SSP-1 activity.
Dependencies are inferred from the claim text.